In fiscal year 2025, Cellbion (308430) reported revenue of 1.9 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 1.9 billion KRW | -8.2 billion KRW | -7.6 billion KRW | [source] |
| 2024 | 2.3 billion KRW | -7.1 billion KRW | -7.3 billion KRW | [source] |
| 2023 | 1.5 billion KRW | -5.0 billion KRW | -3.6 billion KRW | — |
| 2022 | 1.8 billion KRW | -5.3 billion KRW | -6.4 billion KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 35.2 billion KRW | 12.4 billion KRW | 22.8 billion KRW | [source] |
| 2024 | 34.4 billion KRW | 4.8 billion KRW | 29.6 billion KRW | [source] |
| 2023 | — | — | — | — |
| 2022 | — | — | — | — |
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.